Items where Subject is "RS Pharmacy and materia medica"

  • Library of Congress subjects (96930)
  • R Medicine (9332)
  • RS Pharmacy and materia medica (231)
    Number of items at this level: 231.
    Article
  • Evaluation of medication reviews conducted by community pharmacists: a quantitative analysis of documented issues and recommendations. UNSPECIFIED
  • Patients’ experiences of a community pharmacy-led medicines management service. UNSPECIFIED
  • Pharmaceutical policies in a crisis? Challenges and solutions identified at the PPRI Conference. UNSPECIFIED
  • A review of NICE appraisals of pharmaceuticals 2000-2016 found variation in establishing comparative clinical effectiveness. (2018) Anderson, Michael; Naci, Huseyin; Morrison, Deborah; Osipenko, Leeza; Mossialos, Elias
  • Evaluating the benefits of new drugs in health technology assessment using multiple criteria decision analysis: a case study on metastatic prostate cancer with the dental and pharmaceuticals benefits agency (TLV) in Sweden. Angelis, Aris
  • Multiple Criteria Decision Analysis (MCDA) for evaluating new medicines in Health Technology Assessment and beyond: the Advance Value Framework. Angelis, Aris; Kanavos, Panos
  • Advancing structured decision-making in drug regulation at the FDA and EMA. Angelis, Aris; Phillips, Lawrence D. picture_as_pdf
  • To switch or not to switch? Patient attitudes towards generic substitution in Greece. Athanasakis, Kostas; Kyriopoulos, Ilias; Kyriopoulos, John
  • Book review: Wellcome & co.: knowledge, trust, profit and the transformation of the British pharmaceutical industry, 1880-1940. Bakker, Gerben
  • Study of the use of antidepressants for depression in dementia: the HTA -SADD trial - a multicentre, randomised, double-blind, placebo-controlled trial of the clinical effectiveness and cost-effectiveness of sertraline and mirtazapine. Banerjee, Sube; Hellier, J; Romer, R; Dewey, M; Knapp, Martin; Ballard, C; Baldwin, Robert; Bentham, Peter; Fox, C.; Holmes, Clive; Katona, Cornelius; Livingston, G.; Lawton, C; McCrae, N; Moniz-Cook, E; Murray, J; Nurock, J; Orrell, Martin; O'Brien, J; Poppe, M; Thomas, A; Walwyn, R; Wilson, K; Burns, A; Lindesay, James
  • Linear Categorical Marginal Modeling of solicited symptoms in vaccine clinical trials. Bergsma, W. P.; Aris, E. M. D.; Tibaldi, F. S.
  • Optimum design of experiments for enzyme inhibition kinetic models. Bogacka, Barbara; Patan, Maciej; Johnson, Patrick, J; Youdim, K; Atkinson, Anthony C.
  • Creative compliance in pharmaceutical markets: the case of profit controls. Bradley, James; Vandoros, Sotiris
  • Public funding of pharmaceuticals in the Netherlands: investigating the effect of evidence, process and context on CVZ decision-making. Cerri, Karin H.; Knapp, Martin; Fernandez, Jose-Luis
  • Learning lessons from electronic prescribing implementations in secondary care. Cornford, Tony; Savage, Imogen; Jani, Yogini; Franklin, Bryony Dean; Barber, Nick; Slee, Ann; Jacklin, Ann
  • Deregulation and access to medicines: the Peruvian experience. Costa-Font, Joan
  • Regulation effects on the adoption of new medicines. Costa-Font, Joan; McGuire, Alistair; Varol, Nebibe
  • Physician altruism and moral hazard:(no) evidence from Finnish national prescriptions data. Crea, Giovanni; Galizzi, Matteo M.; Linnosmaa, Ismo; Miraldo, Marisa picture_as_pdf
  • Dealing with uncertainty and high prices of new medicines: a comparative analysis of the use of managed entry agreements in Belgium, England, the Netherlands and Sweden. Ferrario, Alessandra; Kanavos, Panos picture_as_pdf
  • An in-depth analysis of pharmaceutical regulation in the Republic of Moldova. Ferrario, Alessandra; Sautenkova, Nina; Bezverhni, Zinaida; Seicas, Rita; Habicht, Jarno; Kanavos, Panos; Safta, Vladimir
  • What the national IT programme means for pharmacy and pharmacists. Gandecha, Reshma; Klecun, Ela; Jacklin, Ann; Williams, Simon
  • Valuing the extended role of prescribing pharmacist in general practice: results from a discrete choice experiment. Gerard, Karen; Tinelli, Michela; Latter, Sue; Blenkinsopp, Alison; Smith, Alesha
  • On compulsory licensing of trade secrets to safeguard public health. (2025) Gurgula, Olga; Luke, David picture_as_pdf
  • Mechanisms of regulatory capture:testing claims of industry influence in the case of Vioxx. Heims, Eva; Moxon, Sophie picture_as_pdf
  • Medicare drug price negotiation:the complexities of selecting therapeutic alternatives for estimating comparative effectiveness. Hernandez, Inmaculada; Cousin, Emma; Wouters, Olivier J.; Gabriel, Nico; Cameron, Teresa; Sullivan, Sean D. picture_as_pdf
  • Measures of effectiveness in medical research:reporting both absolute and relative measures. (2021) Hoefer, Carl; Krauss, Alexander picture_as_pdf
  • Clinical and economic consequences of medication non-adherence in the treatment of patients with a manic/mixed episode of bipolar disorder: results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) Study. Hong, Jihyung; Reed, Catherine; Novick, Diego; Haro, Josep Maria; Aguado, Jaume
  • Nursing home placement in the Donepezil and Memantine in moderate to severe Alzheimer's disease (DOMINO-AD) trial: secondary and post-hoc analyses. Howard, Robert; McShane, Rupert; Lindesay, James; Ritchie, Craig; Baldwin, Ashley; Barber, Robert; Burns, Alistair; Dening, Tom; Findlay, David; Holmes, Clive; Jones, Robert; Jones, Roy; McKeith, Ian; Macharouthu, Ajay; O'Brien, John; Sheehan, Bart; Juszczak, Edmund; Katona, Cornelius; Hills, Robert; Knapp, Martin; Ballard, Clive; Brown, Richard G; Banerjee, Sube; Adams, Jessica; Johnson, Tony; Bentham, Peter; Phillips, Patrick P J
  • A case for the adoption of pharmacoeconomic guidelines in Japan. Ikeda, S.; Ikegami, N.; Oliver, Adam; Ikeda, M.
  • Regulatory consequences of “Brexit” for the development of medicinal products. Jackson, Emily; Feldschreiber, P; Breckenridge, A
  • Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Round Table of the European Society of Cardiology. Jackson, N.; Atar, D.; Borentain, M.; Breithardt, G.; van Eickels, M.; Endres, M.; Fraass, U.; Friede, T.; Hannachi, H.; Janmohamed, S.; Kreuzer, J.; Landray, M.; Lautsch, D.; Le Floch, C.; Mol, P.; Naci, H.; Samani, N. J.; Svensson, A.; Thorstensen, C.; Tijssen, J.; Vandzhura, V.; Zalewski, A.; Kirchhof, P.
  • The MEDMAN study: a randomized controlled trial of community pharmacy-led medicines management for patients with coronary heart disease. Jaffray, Mariesha; Bond, Christine M.; Watson, M. C.; Hannaford, Philip; Tinelli, Michela; Scott, A.; Lee, A.; Blenkinsopp, Alison; Anderson, Cameron; Avery, Anthony; Bissell, P.; Krksa, J.
  • Spain: the effect of country of birth on patterns of pharmaceutical use. Jiménez Rubio, Dolores; Hernández-Quevedo, Cristina
  • Assessing pricing and reimbursement policies for generic pharmaceuticals in the MENA region for improved efficiency, affordability and generic penetration. (2021) Kamphuis, Bregtje W.; Kanavos, Panos picture_as_pdf
  • Financing pharmaceuticals in transition. Kanavos, Panos
  • Acquiring pharmaceutical industry assets in the UK: 1 + 1 = 1? Kanavos, Panos; Angelis, Aris
  • An EU-wide approach to HTA:an irrelevant development or an opportunity not to be missed? Kanavos, Panos; Angelis, Aris; Drummond, Michael
  • Outstanding regulatory issues in the European Union pharmaceutical market. Kanavos, Panos; Mossialos, Elias
  • What is wrong with orphan drug policies?: suggestions for ways forward. Kanavos, Panos; Nicod, Elena
  • Determinants of branded prescription medicine prices in OECD countries. Kanavos, Panos; Vandoros, Sotiris
  • Pricing of in-patent pharmaceuticals in the Middle East and North Africa:is external reference pricing implemented optimally? Kanavos, Panos; Kamphuis, Bregtje; Fontrier, Anna-Maria; Parkin, Georgia Colville; Saleh, Shadi; Akhras, Kasey S. picture_as_pdf
  • The correlation between HTA recommendations and reimbursement status of orphan drugs in Europe. Kawalec, Paweł; Sagan, Anna; Pilc, Andrzej
  • Fertility history and use of antidepressant medication in late mid-life: a register-based analysis of Norwegian women and men. Kravdal, Øystein; Grundy, Emily; Skirbekk, Vegard
  • Levels and determinants of over-prescribing of antibiotics in the public and private primary care sectors in South Africa. (2023) Lagarde, Mylène; Blaauw, Duane picture_as_pdf
  • Crisis management in community pharmacies during a pandemic. (2024) Latonen, S.; Neuvonen, E.; Juppo, A. M.; Seeck, H.; Airaksinen, M. picture_as_pdf
  • Crisis management in the pharmaceutical industry during the COVID-19 pandemic. (2025) Latonen, S.; Pussila, S.; Seeck, H.; Airaksinen, M.; Juppo, A. M. picture_as_pdf
  • Structured approaches to benefit-risk assessment: a case study and the patient perspective. Levitan, Bennett; Phillips, Lawrence D.; Walker, Stuart
  • Antidepressant use in 27 European countries: associations with sociodemographic, cultural and economic factors. Lewer, D.; O'Reilly, C.; Mojtabai, R.; Evans-Lacko, S.
  • Modernising the business of health: pharmaceuticals in Britain, in comparison with Germany and the United States, 1890-1940. Liebenau, Jonathan
  • Cost-utility of cognitive behavioral therapy versus U.S. Food and Drug Administration recommended drugs and usual care in the treatment of patients with fibromyalgia: an economic evaluation alongside a 6-month randomized controlled trial. Luciano, Juan V.; D’Amico, Francesco; Cerdà-Lafont, Marta; Peñarrubia-María, María T.; Knapp, Martin; Cuesta-Vargas, Antonio I.; Serrano-Blanco, Antoni; García-Campayo, Javier
  • Costing infectious disease outbreaks for economic evaluation. Luyten, Jeroen; Beutels, Philippe
  • Kicking against the pricks: vaccine sceptics have a different social orientation. Luyten, Jeroen; Desmet, Pieter; Dorgali, Veronica; Hens, Niel; Beutels, Philippe
  • Public preferences over efficiency, equity and autonomy in vaccination policy: an empirical study. Luyten, Jeroen; Dorgali, Veronica; Hens, Niel; Beutels, Philippe
  • Imputing QALYs from single time point health state descriptions on the EQ-5D and the SF-6D: a comparison of methods for hepatitis A patients. Luyten, Jeroen; Marais, Christiaan; Hens, Niel; De Schrijver, Koen; Beutels, Philippe
  • Cost-effectiveness of hepatitis A vaccination for adults in Belgium. Luyten, Jeroen; Van de Sande, Stefaan; De Schrijver, Koen; Van Damme, Pierre; Beutels, Philippe
  • Vaccination policy and ethical challenges posed by herd immunity, suboptimal uptake and subgroup targeting. Luyten, Jeroen; Vandevelde, Antoon; Van Damme, Pierre; Beutels, Philippe
  • VP164 Applying health technology assessment to pharmacy: the Italian-Medicine-Use-Review-Health Technology Assessment. Manfrin, Andrea; Knapp, Martin; Cicchetti, Americo; Mandelli, Andrea; Tinelli, Michela
  • Why do some countries approve a cancer drug and others don't? Maynou-Pujolras, Laia; Cairns, John
  • The association of a critical care electronic prescribing system with the quality of patient care provided by clinical pharmacists - a prospective, observational cohort study. Mehta, Reena; Onatade, Raliat; Vlachos, Savvas; Sloss, Rhona; Maharaj, Ritesh picture_as_pdf
  • Pharmaceutical patent term extension and patent prosecution in Brazil (1997-2018). (2022) Mercadante, Eduardo; Paranhos, Julia picture_as_pdf
  • Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA. (2022) Michaeli, Daniel Tobias; Mills, Mackenzie; Michaeli, Thomas; Miracolo, Aurelio; Kanavos, Panos picture_as_pdf
  • From "retailers" to health care providers: transforming the role of community pharmacists in chronic disease management. Mossialos, Elias; Courtin, Emilie; Naci, Huseyin; Benrimoj, Shalom; Bouvy, Marcel; Farris, Karen; Noyce, Peter; Sketris, Ingrid picture_as_pdf
  • Balancing benefit and risk of medicines: a systematic review and classification of available methodologies. Mt-Isa, Shahrul; Hallgreen, Christine E.; Wang, Nan; Callréus, Torbjörn; Genov, Georgy; Hirsch, Ian; Hobbiger, Stephen F.; Hockley, Kimberley S.; Luciani, Davide; Phillips, Lawrence D.; Quartey, George; Sarac, Sinan B.; Stoeckert, Isabelle; Tzoulaki, Ioanna; Micaleff, Alain; Ashby, Deborah
  • Medicines dispensers' knowledge on the implementation of an artemisinin-based combination therapy policy for the treatment of uncomplicated malaria in Tanzania. Mwita, Stanley; Jande, Mary; Marwa, Karol; Hamasaki, Kayo; Katabalo, Deogratius; Burger, Johanita; Godman, Brian; Ferrario, Alessandra; Massele, Amos; Ruganuza, Deodatus
  • Double failure: the shared accountability of governments and firms for the innovation deficit in the pharmaceutical sector. Naci, Huseyin; Carter, Alexander W.; Mossialos, Elias picture_as_pdf
  • Why the drug development pipeline is not delivering better medicines. Naci, Huseyin; Carter, Alexander W.; Mossialos, Elias
  • Timing and characteristics of cumulative evidence available on novel therapeutic agents receiving Food and Drug Administration accelerated approval. Naci, Huseyin; Wouters, Olivier J.; Gupta, Radhika; Ioannidis, John P. A.
  • Specialty drugs:a distinctly American phenomenon. Naci, Huseyin; Kesselheim, Aaron S. picture_as_pdf
  • Generating comparative evidence on new drugs and devices before approval. Naci, Huseyin; Salcher-Konrad, Maximilian; Kesselheim, Aaron S.; Dr.rer.nat, Beate Wiesler; Rochaix, Lise; Redberg, Rita; Salanti, Georgia; Jackson, Emily; Garner, Sarah; Stroup, Scott; Cipriani, Andrea picture_as_pdf
  • HTA programme response to the challenges of dealing with orphan medicinal products: process evaluation in selected European countries. Nicod, Elena; Annemans, Lieven; Bucsics, Anna; Lee, Anne; Upadhyaya, Sheela; Facey, Karen
  • The Japanese government's pharmaceutical policy and its effect on hospital financial viability. Oliver, Adam; Ikegami, N.; Ikeda, S.
  • Cost-effectiveness comparisons between antidepressant treatments in depression: evidence from database analyses and prospective studies. Pan, Yi-Ju; Knapp, Martin; McCrone, Paul R.
  • Is quantitative benefit–risk modelling of drugs desirable or possible? Phillips, Lawrence D.; Fasolo, Barbara; Zafiropoulos, Nikolaos; Beyer, Andrea
  • What are the economic barriers of antibiotic R&D and how can we overcome them? Renwick, Mathew; Mossialos, Elias
  • A comparative study of drug listing recommendations and the decision-making process in Australia, the Netherlands, Sweden, and the UK. Salas-Vega, Sebastian; Bertling, Annika; Mossialos, Elias
  • Relationship between costs and clinical benefits of new cancer medicines in Australia, France, the UK, and the US. Salas-Vega, Sebastian; Shearer, Emily; Mossialos, Elias picture_as_pdf
  • Approval of cancer drugs with uncertain therapeutic value:a comparison of regulatory decisions in Europe and the United States. Salcher-Konrad, Maximilian; Naci, Huseyin; Davis, Courtney picture_as_pdf
  • Drug patenting in India: looking back andlooking forward. Sampat, Bhaven N.; Shadlen, Kenneth C.
  • Challenges to India's pharmaceutical patent laws. Sampat, Bhaven N.; Shadlen, Kenneth C.; Amin, Tahir M.
  • Medical cannabis in the UK:from principle to practice. Schlag, Anne Katrin; Baldwin, David S.; Barnes, Michael; Bazire, Steve; Coathup, Rachel; Curran, H. Valerie; McShane, Rupert; Phillips, Lawrence D.; Singh, Ilina; Nutt, David J. picture_as_pdf
  • Information and diffusion of new prescription drugs. Serra-Sastre, Victoria; McGuire, Alistair
  • The political contradictions of incremental innovation: lessons from pharmaceutical patent examination in Brazil. Shadlen, Kenneth C.
  • Indian pharmaceutical patent prosecution: the changing role of Section 3(d). Shadlen, Kenneth C.; Sampat, Bhaven N.
  • Patents, trade, and medicines:past, present, and future. Shadlen, Kenneth C.; Sampat, Bhaven N.; Kapczynski, Amy picture_as_pdf
  • Association between preapproval confirmatory trial initiation and conversion to traditional approval or withdrawal in the FDA accelerated approval pathway. (2023) Shahzad, Mahnum; Naci, Huseyin; Wagner, Anita K.
  • Investing in health R&D:where we are, what limits us, and how to make progress in Africa. Simpkin, Victoria; Namubiru-Mwaura, Evelyn; Clarke, Lorcan; Mossialos, Elias picture_as_pdf
  • Application-specific R&D capabilities and the advantage of incumbents: evidence from the anticancer drug market. Sosa, M. Lourdes
  • Decoupling market incumbency from organizational prehistory: locating the real sources of competitive advantage in R&D for radical innovation. Sosa, M. Lourdes
  • Analysis of prices paid by low-income countries: how price sensitive is government demand for medicines? Srivastava, Divya; McGuire, Alistair
  • Understanding support for complementary and alternative medicine in general populations:Use and perceived efficacy. Stoneman, Paul; Sturgis, Patrick; Allum, Nick
  • The consequences of pharmaceutical tariffs in the United States. (2025) Sullivan, Sean D.; Grueger, Jens; Sullivan, Aidan P.; Ramsey, Scott D.
  • Integrating price benchmarks and comparative clinical effectiveness to inform the medicare drug price negotiation program. (2024) Sullivan, Sean D.; Wouters, Olivier J.; Cousin, Emma M.; Kirihennedige, Ayuri S.; Hernandez, Inmaculada picture_as_pdf
  • Novartis v Union of India and the person skilled in the art: a missed opportunity. Thambisetty, Sivaramjani
  • Improving access to patented medicines:are human rights getting in the way? Thambisetty, Sivaramjani picture_as_pdf
  • Better outcomes for the patient, the provider and the society now: this is not a dream, and the pharmacist could help! Tinelli, Michela
  • Costi dell’aterosclerosi. Tinelli, Michela
  • Neuropatie diabetiche ed L-carnitina: nuove prospettive di trattamento. Tinelli, Michela
  • Survey of patients' experiences and perceptions of care provided by nurse and pharmacist independent prescribers in primary care. Tinelli, Michela; Blenkinsopp, Alison; Latter, Sue; Smith, Alesha; Chapman, Stephen R.
  • The MEDMAN project: evaluation of the medicines management training for community pharmacists. Tinelli, Michela; Jaffray, M; Krksa, J.; Bond, Christine M.
  • Economic evaluation advancement in pharmacy: discrete choice experiments (DCEs). Tinelli, Michela; Ryan, M.; Bond, Christine
  • Session 1A: methods. Discrete choice experiments (DCEs) to inform pharmacy policy: going beyond Quality Adjusted Life Years (QALYs). Tinelli, Michela; Ryan, M.; Bond, Christine
  • Patient-centred approach to policy development: a pharmacy-led medicines management service. Tinelli, Michela; Ryan, Mandy; Bond, Christine
  • Novel pharmacist-led intervention secures the minimally important difference (MID) in Asthma Control Test (ACT) score: better outcomes for patients and the healthcare provider. Tinelli, Michela; White, John; Manfrin, Andrea picture_as_pdf
  • Parallel trade and pharmaceutical prices: a game-theoretic approach and empirical evidence from the European Union. Vandoros, Sotiris; Kanavos, Panos
  • Challenges and opportunities for pharmaceutical pricing and reimbursement policies. Vogler, Sabine; Zimmermann, Nina; Ferrario, Alessandra; Wirtz, Veronika J; Babar, Zaheer-Ud-Din
  • The effects of drug market regulation on pharmaceutical prices in Europe: overview and evidence from the market of ACE inhibitors. Von der Schulenburg, Fritz; Vandoros, Sotiris; Kanavos, Panos
  • Decision making under uncertainty:comparing regulatory and health technology assessment reviews of medicines in the United States and Europe. Vreman, Rick A.; Naci, Huseyin; Goettsch, Wim G.; Mantel-Teeuwisse, Aukje K.; Schneeweiss, Sebastian G.; Leufkens, Hubert G.M.; Kesselheim, Aaron S. picture_as_pdf
  • The first English histories of pharmacy - their origins and influences. Wallis, Patrick
  • Cancer drug indication approvals in China and the United States:a comparison of approval times and clinical benefit, 2001–2020. Wei, Yuxuan; Zhang, Yichen; Xu, Ziyue; Wang, Guoan; Zhou, Yue; Li, Huangqianyu; Shi, Luwen; Naci, Huseyin; Wagner, Anita K.; Guan, Xiaodong picture_as_pdf
  • The impact of alternative pricing methods for drugs in California Workers’ Compensation System: fee-schedule pricing. Wilson, Leslie; Turkistani, Fatema A.; Huang, Wei; Tran, Dang M.; Kuo Lin, Tracy
  • Transitioning to a national health system in Cyprus: a stakeholder analysis of pharmaceutical policy reform. Wouters, Olivier J.; Kanavos, Panos
  • A comparison of generic drug prices in seven European countries: a methodological analysis. Wouters, Olivier J.; Kanavos, Panos
  • Sales revenues for new therapeutic agents approved by the United States Food and Drug Administration from 1995 to 2014:a retrospective study. (2024) Wouters, Olivier J.; Kesselheim, Aaron S.; Kuha, Jouni; Luyten, Jeroen picture_as_pdf
  • Combating substandard and falsified medicines in China:policy barriers and the role of pharmaceutical track-and-trace systems. Xin, Tangsiwei picture_as_pdf
  • Evaluating benefit-risk: an Agency perspective. Zafiropoulos, Nikolaos; Phillips, Lawrence D.; Pignatti, Francesco; Luria, Xavier
  • Patient’s perception of medication and nonadherence to chronic disease treatments. A population-based study in Brazil. da Silva Menolli, Poliana Vieira; Brummel, Adriana Mitsue Ivama; Guidoni, Camilo Molino; Girotto, Edmarlon picture_as_pdf
  • Ranking the harm of non-medically used prescription opioids in the UK. van Amsterdam, Jan; Phillips, Lawrence D.; Henderson, Graeme; Bell, James; Bowden-Jones, Owen; Hammersley, Richard; Ramsey, John; Taylor, Polly; Dale-Perera, Annette; Melichar, Jan; van den Brink, Wim; Nutt, David
    • Book
  • Intellectual property, pharmaceuticals and public health: access to drugs in developing countries. UNSPECIFIED
    • Chapter
  • Regulation as global drug governance: how new is the NPS phenomenon? Collins, John picture_as_pdf
  • The politics of the EU pharmaceutical industry. Permanand, Govin; Altenstetter, Christa
  • Benefit-risk modeling of medicinal products: methods and applications. (2013) Phillips, Lawrence D.
  • The politics of patents and drugs in Brazil and Mexico: the industrial bases of health policies. (2011) Shadlen, Kenneth C.
  • Globalization, intellectual property rights, and pharmaceuticals: meeting the challenges to addressing health gaps in the new international environment. Shadlen, Kenneth C.; Guennif, Samira; Guzmán, Alenka; Lalitha, N.
    • Conference or Workshop Item
  • Community pharmacists’ attitudes and knowledge of medicines management. UNSPECIFIED
  • Community pharmacists’ perceptions and experiences of interprofessional collaboration with general practitioners. UNSPECIFIED
  • Evaluating patient feedback on a new medicines management service provided by community pharmacists. UNSPECIFIED
  • Evaluation of the Community Pharmacy Medicines Management Project. UNSPECIFIED
  • General Practitioners’ opinions of and attitudes towards a community pharmacist-led medicines management service for patients with coronary heart disease. UNSPECIFIED
  • General Practitioners’ perceptions of interprofessional collaboration with community pharmacists. UNSPECIFIED
  • Practice staff’s views on a community pharmacy-led medicines management service. UNSPECIFIED
  • What patients want from a pharmacy-led medicines management service. UNSPECIFIED
  • Knowledge production vs knowledge management: the case of pharmaceutical R&D. Cordella, Antonio
  • Distributed knowledge across boundaries. Cordella, Antonio; Grisot, M.
  • Competition issues in the distribution of pharmaceuticals. Kanavos, Panos; Wouters, Olivier J.
  • Concurrence dans la distribution de produits pharmaceutiques. Kanavos, Panos; Wouters, Olivier J.
  • Community pharmacists and drug misusers: national trends in attitudes and current practice. Matheson, Catriona; Bond, C.; Tinelli, Michela
  • VP164: Applying HTA to pharmacy: the Italian-Medicine-Use-Review-HTA. Tinelli, Michela; Manfrin, Andrea; Knapp, Martin; Mandelli, A.
    • Report
  • Benefit-risk methodology project:update on work package 5: effects table pilot (phase I). UNSPECIFIED
  • Benefit-risk methodology project:work package 1 report: description of the current practice of benefit-risk assessment for centralised procedure products in the EU regulatory network. UNSPECIFIED
  • Benefit-risk methodology project:work package 2 report: applicability of current tools and processes for regulatory benefit-risk assessment. UNSPECIFIED
  • Benefit-risk methodology project:work package 3 report: field tests. UNSPECIFIED
  • Benefit-risk methodology project:work package 4 report: benefit-risk tools and processes. UNSPECIFIED
  • Differences in costs of and access to pharmaceutical products in the EU. UNSPECIFIED
  • Regulation of healthcare advertisements: comparing media regulation of the pharmaceutical industry in Kuwait and the GCC. Alkazemi, Mariam
  • Evaluatie van universele en doelgroep hepatitis A vaccinatie opties in België = Evaluation of universal and targeted hepatitis A vaccination programs in Belgium. Beutels, Philippe; Luyten, Jeroen; Lejeune, Olivier; Hens, Niel; Bilcke, Joke; De Schrijver, Koen; Van de Sande, Stefaan; Van Herck, Koen; Van Damme, Pierre
  • Tender Loving Care? Purchasing medicines for continuing therapeutic improvement and better health outcomes. Bonser, Andrew; Kanavos, Panos; Taylor, David
  • Managed entry agreements for pharmaceuticals: the European experience. Ferrario, Alessandra; Kanavos, Panos
  • The evaluation of the electronic prescription service in primary care: interim report on the findings from the evaluation in early implementer sites. Hibberd, Ralph; Barber, Nick; Cornford, Tony; Lichtner, Valentina
  • IMI-PROTECT benefit-risk grouprecommendations report:recommendations for the methodology andvisualisation techniques to be used in theassessment of benefit and risk of medicines. Hughes, Diana; Waddingham, Ed, A., J.; Mt-Isa, Shahrul; Goginsky, Alesia; Chan, Edmond; Downey, Gerald; Hallgreen, Christine E.; Hockley, Kimberley S.; Juhaeri, Juhaeri; Lieftucht, Alfons; Metcalfe, Marilyn, A.; Noel, Rebecca, A.; Phillips, Lawrence D.; Ashby, Deborah; Micaleff, Alain
  • The Community Pharmacy Medicines Management Project: final report. Jaffray, Mariesha; Bond, Christine; Tinelli, Michela
  • The European pharmaceutical market and policies - outlook for the future. Kanavos, Panos; Vandoros, Sotiris; Irwin, Rachel; Nicod, Elena; Casson, Margaret
  • IMI work package 5: report 1:b:iii benefit - riskwave 1 case study report:Raptiva® (efalizumab). Micaleff, Alain; Callreus, Tornbjorn; Phillips, Lawrence D.; Hughes, Diana; Hockley, Kimberley; Wang, Nan; Luciani, David
  • Policy options for pharmaceutical research and development in the European Community. Mossialos, Elias; Kanavos, Panos; Abel-Smith, B.
  • The regulation of pharmacies in six countries: report prepared for the Office of Fair Trading. Mossialos, Elias; Mrazek, Monique F.
  • Pharmaceutical policies in Finland - challenges and opportunities. Mossialos, Elias; Srivastava, Divya
  • Review of visualisation methods for therepresentation of benefit-risk assessment ofmedication: stage 2 of 2. Mt-Isa, Shahrul; Hallgreen, Christine, E.; Asiimwe, Alex; Downey, Gerry; Genov, Georgy; Hermann, Richard; Hughes, Diana; Lieftucht, Alfons; Noel, Rebecca; Peters, Ruth; Phillips, Lawrence D.; Shepherd, Susan; Micaleff, Alain; Ashby, Deborah; Tzoulak, Ioanna
  • Review of visualisation methods for therepresentation of benefit-risk assessment ofmedication: Stage 1 of 2. Mt-Isa, Shahrul; Peters, Ruth; Phillips, Lawrence D.; Chan, Kakit; Hockley, Kimberley S.; Wang, Nan; Ashby, Deborah; Tzoulak, Ioanna
  • IMI work package 5: report 2:b:ii benefit - riskwave 2 case study report: Rosiglitazone. Phillips, Lawrence D.; Amzal, Billy; Asiimwe, Alex; Chan, Edmond; Chen, Chen; Hughes, Diana; Juhaeri, Juhaeri; Micaleff, Alain; Mt-Isa, Shahrul; Noel, Becky; Shepherd, Susan; Wang, Nan
    • Thesis
  • Developing and applying discrete choice experiments (DCEs) to inform pharmacy policy. Tinelli, Michela
    • Online resource
  • Why are the prices of new medicines so high and what can we do about it? (F8). Angelis, Aris
  • MMR, the media and risk. Beckett, Charlie
  • Pharma online: does regulation or corporate social media policy need to change to allow a real dialogue about medicines? Cohen, Lucía
  • The digital future beyond the pill. Cornford, Tony
  • How important is patient brand loyalty in the uptake of generic drugs? Costa-Font, Joan; Rudisill, Caroline; Stefanie, Tan
  • Parallel trade in medicinal drugs is putting the welfare of EU patients at risk. Costa-i-Font, Joan
  • The war over drugs: what’s at stake? Coulter, Steve
  • $1 million for a drug used once. Dickson, Jane
  • 165,000 and counting! Dickson, Jane
  • Books about the future of medicine, digital doctors, patient safety etc. Dickson, Jane
  • D3 Research presents a poster at the LSE Research Festival. Dickson, Jane
  • The D3 project. Dickson, Jane
  • Digital necklace wins Unicef award. Dickson, Jane
  • E-prescribing and ADE in primary care – data and evidence from meaningful use in the US. Dickson, Jane
  • Enduring and emerging challenges of informed consent. Dickson, Jane
  • Mental health monitoring through ‘selfie’ videos and social media tracking. Dickson, Jane
  • NHS England initiative: ‘combinatorial innovation’ in NHS test beds. Dickson, Jane
  • National systems of patient unique identifiers – nations pro and against. Dickson, Jane
  • Non-adherence to prescriptions is categorical construct. Non-persistence adds a time dimension to it. Dickson, Jane
  • Personalized medicine: a podcast. Dickson, Jane
  • Pharmacogenetics test lab embedded in ePrescribing, for personalised medicine? Dickson, Jane
  • Precision medicine on BBC Radio 4 Today Programme. Dickson, Jane
  • Research hypothesis and objectives. Dickson, Jane
  • Results of latest international action on counterfeit and unlicensed medicines. Dickson, Jane
  • Serialisation of individual pills to defeat counterfeiters. Dickson, Jane
  • Shining a light on Lumosity’s claims. Dickson, Jane
  • Sounds like a diagnosis? Dickson, Jane
  • Stratified medicine in 2015 – Leeds Christmas lecture. Dickson, Jane
  • Tackling the problem of sub-standard therapeutic drugs in Kenya. Dickson, Jane
  • Testing & mental health apps. Dickson, Jane
  • Type 1 diabetes breakthrough. Dickson, Jane
  • Vita brevis ars longa: feeding Watson on dubious data. Dickson, Jane
  • Vocal biomarkers: diagnostics through human voice. Dickson, Jane
  • Warfarin history timeline. Dickson, Jane
  • Worrying about data. Dickson, Jane
  • A decision support tool for warfarin prescribing. Dickson, Jane
  • How academics and service providers are working together to inform drug policy in Ireland. Duffin, Tony
  • Why is doping wrong anyway? Dyke, Heather
  • Cost of depression in the workplace across eight diverse countries – collectively US$250 billion. Evans-Lacko, Sara; Knapp, Martin
  • Accelerating access to new drugs in Japan. Hibberd, Ralph
  • Brexit and the falsified medicines directive. Hibberd, Ralph
  • Combating falsified medicines in Africa through digital artefacts. Hibberd, Ralph
  • Hub and spoke dispensing: privacy and sociotechnical rigidity. Hibberd, Ralph
  • Hub and spoke dispensing: safety and sociotechnical pliability. Hibberd, Ralph
  • ‘the little liar’ – patient information about medicines. Lichtner, Valentina
  • Using international human rights law to guarantee the right to health: a Brazilian experience. Morais de Oliveira, Iago
  • Building a strong pharmaceutical system for China. Mossialos, Elias; Ge, Yanfeng; Hu, Jia; Wang, Liejun
  • What works best in congenital heart disease? Comparing two interventions for treatment of Aortic Coarctation. Olczak, Kaya; Salcher, Maximillian; Naci, Huseyin
  • Why social media is good for medicine and why pharmaceutical companies should engage online. Relle, Katherine
  • Targeting innovation in antibiotics. Renewick, Matthew; Simpkin, Victoria; Mossialos, Elias
  • Debating Patents and Drug Prices: Trade Agreements and the Trans-Pacific Partnership. Shadlen, Kenneth C.
  • Learning from India? A new approach to secondary pharmaceutical patents. Shadlen, Kenneth C. picture_as_pdf
  • Balancing innovation and access: India’s pharmaceutical patent laws. Shadlen, Kenneth C.; Sampat, Bhaven N.; Amin, Tahir M. picture_as_pdf
  • Compulsory licenses for pharmaceuticals: an inconvenient truth? Thambisetty, Sivaramjani
  • In Italy primary care prescriptions all electronic from 1 March 2016. Vazza, Lucilla
  • Long read review: drug dealer, MD: how doctors were duped, patients got hooked and why it’s so hard to stop by Anna Lembke. Williams, Thomas Christie
    • Working paper
  • Patents and the global diffusion of new drugs. Cockburn, Iain; Lanjouw, Jean O.; Schankerman, Mark
  • A 'Health Kuznets' curve'? Cross-country and longitudinal evidence. Costa-i-Font, Joan; Hernandez-Quevedo, Christina; Sato, Azusa
  • Does pharmaceutical price regulation affect the adoption of generic competition?: evidence from the OECD, 1999-2008. Costa-i-Font, Joan; Varol, Nebibe; McGuire, Alistair
  • Learning and interest accommodation in policy and institutional change: EC risk regulation in the pharmaceuticals sector. Feick, Jürgen
  • Medical marijuana laws and mental health in the United States. Kalbfuß, Jörg; Odermatt, Reto; Stutzer, Alois
  • Overview of pharmaceutical pricing and reimbursement regulation. Kanavos, Panos
  • Theorising the development of the European Union framework for pharmaceutical regulation. Permanand, Govin; Mossialos, Elias
  • Improving access to patented medicines: are human rights getting in the way? Thambisetty, Sivaramjani
  • Novartis v Union of India and the person skilled in the art: a missed opportunity. Thambisetty, Sivaramjani
  • Do international launch strategies of pharmaceutical corporations respond to changes in the regulatory environment? Varol, Nebibe; Costa-i-Font, Joan; McGuire, Alistair
    • ['eprint_typename_blog_post' not defined]
  • Book review:Enforcing Freedom: Drug Courts, Therapeutic Communities and the Intimacies of the State by Kerwin Kaye. Ford, Alessandro picture_as_pdf
  • Book review:Pills, powder and smoke: inside the bloody war on drugs by Antony Loewenstein. Ford, Alessandro picture_as_pdf
  • How the US states have learned from each other to create more comprehensive medical cannabis policies. Hannah, A. Lee; Mallinson, Daniel J. picture_as_pdf
  • The Covid-19 pandemic means that the running down of US Strategic Stockpile of medicines could not have come at a worse time. Pettus, Katherine picture_as_pdf
  • Drug patenting in India:looking back and looking forward. Shadlen, Kenneth C.; Sampat, Bhaven N. picture_as_pdf
  • Big Pharma must embrace the shift to technological solutions in healthcare. Shaked, Yoav picture_as_pdf